Alcohol Use Disorder, Alcoholism, Alcohol Addiction
Conditions
Brief summary
Alcohol use disorder (AUD) is a chronic relapsing disorder. Alcohol craving, a hallmark symptom of AUD that drives relapse in patients, is only insufficiently treated by existing medication. One promising new compound is Oxytocin (OXY), which showed beneficial effects on alcohol craving in preliminary clinical studies. Additionally, OXY seems to enhance effects of established medication, specifically Naltrexone (NTX), an opioid-antagonist which is approved for AUD treatment via positive synergism on neurotransmitter levels. The proposed two-armed, 1:1 randomized, double-blind, parallel group trial seeks to test the putative synergistic effects of combined intranasal OXY spray (24 IU) + oral NTX (50mg) against Placebo spray + oral NTX (50mg) on alcohol craving (primary outcome) in male and female patients with AUD that suffer from high alcohol craving, within the framework of a validated alcohol cue-and stress-exposure task (i.e. a combined Trier Stress Test and alcohol cue-exposure) that was established for screening new medications in AUD and determine their effects on craving and relapse risk. Treatment effects on additional neurobiological and biochemical markers of craving that show strong associations to individual relapse risk, will serve as secondary outcomes. Collection and analysis of follow-up data (90 days) will be performed to determine whether treatment effects relate to patient outcome. The clinical trial period for an individual participant consists of a screening visit (visit 1), a baseline visit (visit 2) and two treatment visits (visits 3 and 4)(all within equal or less than ten days) followed by a 90 days (+/- 7 days) follow-up phase with two visits (visits 5 and 6) at day 30 (± 7 days) and day 90 (± 7 days). Visits 1 to 4 will be conducted while participants are undergoing standard in-patient treatment at the Department of Addictive Behavior and Addiction medicine at the Central Institute of Mental Health (CIMH) in Mannheim, Germany, for the medical condition under investigation.
Interventions
DRUGPlacebo
Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
DRUGOxytocin nasal spray
24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
DRUGNaltrexone Pill
All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
Sponsors
Heidelberg University - Institute of Medical Biometry (IMBI)
Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University
German Federal Ministry of Education and Research
Central Institute of Mental Health, Mannheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 70 years * Patients meeting the diagnosis of an alcohol dependence according to the Internation Clasification of Diseases 10th revision (ICD10) * Patients with at least moderate craving, i.e. either \>=15 points on the Alcohol Urge Questionnaire (AUQ, range 8 to 56 points) craving scale or increase in AUQ scores by \>= 50% after exposure to visual alcohol cues (i.e. minimum increase of \>=4 points after cue exposure) * Ability of the individual to understand the character and the individual consequences of the clinical trial * Written informed consent (must be available before enrollment in the study) * Consent to random assignment * For women with childbearing potential, use of a highly effective birth control method until 24 hours after Visit 4 and negative pregnancy test
Exclusion criteria
* Subjects presenting with any of the following criteria will not be included in the clinical trial: Current psychotic or bipolar disorder or current severe depressive episode with suicidal ideations * Current treatment with any of the following substances: Any investigational medicinal product, Opioid-containing Analgesics, Anorexics, Anticonvulsants, Opioid-containing Antidiarrheal Agents, Antineoplastics, Antipsychotics (exception: episodic use of melperone, pipamperone and quetiapine are allowed), Antidepressants (exception: allowed, when being taken in stable dose for a minimum of 14 days prior to enrolment and/or doxepin in low doses \[max. 75mg daily\]), Opioid-containing Cough/cold agents, systemic Steroids * Positive drug screening (amphetamines/ecstasy, opiates, cocaine, barbiturates) * Pregnancy, lactation or breastfeeding * Current severe somatic comorbidities: liver cirrhosis \[CHILD B or C\] or impaired renal function \[glomerular filtration rate (GFR)\<15ml/Min\] \[each determined by physical examination and/or laboratory testing\], severe heart insufficiency \[determined by assessment of medical history\], pre-existing epilepsy \[determined by assessment of medical history\], long-QT syndrome or cardial arrhythmia \[determined by ECG\] * History of hypersensitivity to the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone (trade names: Adepend, Naltrexon-Hcl neuraxpharm, Naltrexonhydrochlorid Accord) or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone * Participation in other clinical trials or observation period of competing clinical trials, respectively. * Acute suicidal tendency or acute endangerment of self and others
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alcohol Urge Questionnaire (AUQ) | 60 minutes after oxytocin/placebo application and directly after the combined stress- and cue-exposure will serve as primary outcome measure at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Primary Appraisal secondary Appraisal Scale (PASA) | 35 minutes after oxytocin/placebo application at Visit 3 | Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
| Positive and Negative Affect Schedule (PANAS) | 60 minutes after oxytocin/placebo application at Visit 3 | Positive and Negative Affect will be assessed using the Positive and Negative Affect Schedule (PANAS) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
| Cortisol | 65 minutes after oxytocin/placebo application at Visit 3 | Cortisol plasma levels will be determined using validated Enzyme-linked Immunosorbent Assay (ELISA) methods by the central laboratory at visit 3 after Oxytocin/Placebo administration |
| Oxytocin | 30 minutes after oxytocin/placebo application at Visit 3 | Oxytocin plasma levels will be determined using validated ELISA methods by the central laboratory at visit 3 after Oxytocin/Placebo administration |
| Alcohol Cue-induced neural brain activation during an Alcohol cue-reactivity functional magnetic resonance imaging (fMRI) task | During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration | Neural brain activation in the mesocorticolimbic system (whole-brain and Region-of-Interest Analyses (ROIs): ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response, during presentation of alcohol cues will serve as secondary outcome |
| Neural Activation during a natural reward cue-reactivity fMRI task | During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration | Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response during the presentation of natural reward cues will serve as secondary outcome |
| Alcohol Urge Questionnaire (AUQ) | 35 minutes after oxytocin/placebo application at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Neural Activation during a Stop Signal fMRI Task | During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration | Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, dlPFC), measured using the blood oxygenated level dependent (BOLD) response during a stop signal fMRI task will serve as secondary outcome |
| Adverse Events (AEs)/Serious Adverse Events (SAEs) and Discontinuation rate | During Study Visits 1 to 6, including the 90 day (±7 day) follow-up period | Rate of adverse events, serious adverse events and rate of discontinuation of the study due to an adverse event |
| Subjective quality of life index | At Visit 5, i.e. 30 days (+/- 7 days) after Visit 3 | Quality of life will be assessed using the WHO-QOL-BREF scores |
| Time to relapse during the follow-up period of 90 days (+/- 7 days) | During 90-day (± 7 days) Follow-up | Time from randomization to relapse to alcohol use (in days) |
| Cumulative alcohol consumption during the follow-up period of 90 days (+/- 7 days) | During 90-day (± 7 days) Follow-up | Self-reported cumulative alcohol use (in gram) |
| Percent heavy drinking days during the follow-up period of 90 days (+/- 7 days) | During 90-day (± 7 days) Follow-up | Self-reported percent heavy drinking days (in %) |
| Neural Activation during a Face-matching fMRI task | During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration | Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, amygdala), measured using the blood oxygenated level dependent (BOLD) response during the presentation of emotional faces and neutral shapes will serve as secondary outcome |
Countries
Germany
Outcome results
None listed